The vice president of Innovation and New Technologies at Grifols provided perspective on the interim phase 2 findings of ABvac40, a vaccine in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]
Jose Terencio, PhD
Advertisement
Articles by Jose Terencio, PhD
Advertisement
Latest Updated Articles
Overviewing Preliminary Data of ABvac40, a Vaccine for Alzheimer Disease: Jose Terencio, PhDPublished: November 8th 2023 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS
2
Showcasing Sustained Benefits in Myasthenia Gravis Research at AANEM 2025: Kimberly Moran, PhD, MBA
3
This Week on NeurologyLive® — November 3, 2025
4
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
5
